WELCOME TO The PHARMACEUTICAL REPORT
Newsletter | Member Login | Signup
Home > Companies > Medical Solutions Supplier
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Conference
Webinar
Pharmaceutical Technology | February 25, 2020
Swiss pharma giant Novartis and non-profit research and development organisation Drugs for Neglected Diseases initiative (DNDi) have signed a collaboration and license agreement to jointly develop LXE408 for visceral leishmaniasis. LXE408 is an oral treatment for this parasitic disease, which is transmitted by the bite of a sand fly, and can be life-threatening if left untreated. The drug was initially discovered by Novartis with the financial backing of the Wellcome Trust. DNDi executive direct...
PR Newswire | March 20, 2020
AIkido Pharma Incorporated (Nasdaq: AIKI) today announced the addition of Andreas Typaldos to the Company's Advisory Board.Mr. Typaldos is a pioneer software and technology entrepreneur, and a private equity investor through a Typaldos Family Office. Currently he is founder and Executive Chairman of technology companies in the general AI and specialized AI-driven FinTech and MarTech space, CLOUD computing and IT Infrastructure Management, and enterprise software, including:...
Business Insights, PHARMA TECH
KSQ Therapeutics | January 30, 2023
KSQ Therapeutics, a leading clinical-stage biotechnology company developing therapies to treat cancer and autoimmune diseases, recently announced that Ono Pharmaceutical (ONO) has acquired multiple research-stage DNA damage response (DDR) programs. The programs were identified using KSQ's CRISPRomics platform technology. All of the programs are new and have the potential to be first-in-class therapies. ONO's Discovery & Research Executive Director/ Senior Executive O...
Pharma Tech
Fusion | October 23, 2021
Fusion Pharmaceuticals a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the presentation of preclinical data that provide further support of its FPI-1966 and FPI-2059 targeted alpha therapies at the 34th Annual European Association of Nuclear Medicine Congress. These data reinforce the clinical dosing regimen of FPI-1966 and highlight the potential of FPI-2059 as an actinium-225 labelled precision medicine target...
Article
Pharmacy Market
PHARMACY MARKET
Video
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE